Gene therapy in glaucoma-part I: Basic mechanisms and molecular genetics

Area of Science:

• Ophthalmology
• Genetics
• Public Health

Background:

• Glaucoma is a significant global cause of blindness, posing challenges in diagnosis, risk identification, and treatment timing.
• Despite advancements, blindness from glaucoma remains a major public health concern.
• The role of heredity in ocular diseases is gaining attention due to progress in the Human Genome Project and HapMap Project.

Purpose of the Study:

• To explore the potential of gene therapy and DNA-based diagnostics for glaucoma.
• To highlight the importance of understanding molecular mechanisms and genetic factors in glaucoma treatment.
• To review current knowledge on genetic defects and their implications for novel therapeutic strategies.

Main Methods:

• Literature search conducted on the Medline database via Pubmed interface.
• Review of studies focusing on genetic analysis, risk factors, and therapeutic targets in glaucoma.
• Analysis of advancements in gene therapy and DNA-based diagnosis for ocular diseases.

Main Results:

• Genetic analysis is becoming increasingly feasible for complex disorders like glaucoma.
• Glaucoma presents numerous targets for gene therapy, with potential to modulate risk factors.
• Discovery of glaucoma-associated genes enables development of new DNA-based diagnostic and treatment methods.

Conclusions:

• Genetic defects underlying glaucoma are being identified, paving the way for new therapies.
• Gene therapy holds promise for modulating glaucoma risk factors and underlying causes.
• Ophthalmologists and specialists must be knowledgeable about molecular mechanisms, genes, and genetic treatments for glaucoma.